<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 02:43:33 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>A Three-Part China Merger Strategy For NeoStem (AMEX: NBS)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3537155</guid>
      <description><![CDATA[NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of anti-aging / cosmetic medicine and other stem cell technologies.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3537155>[More...]</a>]]></description>
      <pubDate>Thu, 08 Oct 2009 01:46:52 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3537155</link>
    </item>
    <item>
      <title>NeoStem (AMEX:NBS): Pro-Active Research Initiates As Spec Buy</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3257732</guid>
      <description><![CDATA[NeoStem, Inc. (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious c (...)<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3257732>[More...]</a>]]></description>
      <pubDate>Thu, 04 Jun 2009 16:30:01 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3257732</link>
    </item>
    <item>
      <title>NeoStem (AMEX:NBS) Expands Beyond Stem Cell Banking</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3235470</guid>
      <description><![CDATA[NeoStem (AMEX:NBS) is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consume (...)<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3235470>[More...]</a>]]></description>
      <pubDate>Mon, 18 May 2009 15:59:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3235470</link>
    </item>
    <item>
      <title>US Stem Cell Banking Company Receives Investment from Asia</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2574847</guid>
      <description><![CDATA[NeoStem, Inc. completed a $1.25 million private placement from RimAsia Capital Partners, a pan-Asia private equity firm. This appears to be RimAsia’s first investment in a Western company. Previously, RimAsia's invested only in China-based enterprises. Ac<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2574847>[More...]</a>]]></description>
      <pubDate>Wed, 03 Sep 2008 17:23:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2574847</link>
    </item>
    <item>
      <title>NeoStem to Acquire Stem Cell Technology and Anti-Aging Research Rights</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3060717</guid>
      <description><![CDATA[NeoStem, Inc., a company engaged in pre-disease collection, processing and storage of adult stem cells, has signed a license agreement to obtain the exclusive worldwide rights to innovative stem cell technology and applications for cosmetic facial and body procedures and skin rejuvenation.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3060717>[More...]</a>]]></description>
      <pubDate>Mon, 23 Feb 2009 16:51:16 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3060717</link>
    </item>
    <item>
      <title>NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3434796</guid>
      <description><![CDATA[NeoStem Inc. which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the Company's CEO, Robin Smith, M.D. MBA, has been invited to participate in the 2009 World Stem Cell Summit to be held in Baltimore, Maryland, next month.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3434796>[More...]</a>]]></description>
      <pubDate>Tue, 25 Aug 2009 11:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3434796</link>
    </item>
    <item>
      <title>NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3432975</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that it has qualified as an Emerging Technology Company with the New York Department of Taxation and Finance, for the period ending December 31, 2009.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3432975>[More...]</a>]]></description>
      <pubDate>Mon, 24 Aug 2009 12:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CHBP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CHBP.OB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3432975</link>
    </item>
    <item>
      <title>Stem Cell Treatments in the News: NeoStem Featured on CBS's Eye on New York</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3365656</guid>
      <description><![CDATA[NeoStem, Inc. today announced that the Company was featured on CBS's Eye on New York City on Sunday morning July 19, 2009.The segment focused on NeoStem which is the first company to provide healthy adults in the general public the ability to have their stem cells collected in a safe and non-invasive way. http://www.neostem.com/videolinks.php NeoStem makes it Easy and Painless. Advances in technology allow increased numbers of stem cells residing in your bone marrow, to migrate into the peripheral blood, a process that occurs naturally in the body when there is stress or injury. The next step is apheresis, a painless and safe procedure which separates and collects, through a sterile, closed and disposable system, the stem cells from your peripheral blood. The remaining cells are immediately returned to you. The collection process usually lasts about 3-4 hours. The cells are then cryo-preserved. The feature also discussed therapies which stem cells may be used to treat and referenced the statement of Dr. Max Gomez, CBS2&amp;#39;s medical expert, that autologous adult stem cells &amp;#34;have become the cutting edge way to treat osteoarthritis of the knee, hip, and ankle and even back pain.&amp;#34; He noted, &amp;#34;The promise appears to be so great that more than 1,000 clinical trials are testing stem cell therapies for various conditions and showing promising results for heart failure, diabetes, lupus and even macular degeneration.&amp;#34; According to a recent report of a study Conducted by City of Hope National Medical Center, after undergoing stem cell transplantation patients developing secondary acute myeloid leukemia/myelodysplastic disease following adjuvant treatment for breast cancer can achieve durable remission. 'NeoStem is very focused on autologous adult stem cell therapies being developed for multiple diseases,&amp;#34; says Dr. Robin Smith, Chief Executive Officer of NeoStem. The Company has entered into a number of licensing arrangements. including acquisition of a worldwide exclusive license to technology to identify and isolate VSELs , which have been shown to have several physical characteristics that are generally found in embryonic stem cells. NeoStem's technologies to advance its position in the field of stem cell tissue regeneration has caught the interest of other publications. NeoStem was also featured in the Summer 2009 issue of Catalyst, a magazine of Connections, Developments and Insights in the Life Science Industry. This publication by Amper, Politziner and Mattia focused this issue on Pharmaceuticalization of stem cells and featured Celgene Cellular Therapeutics which is focused on stem cell therapies from human placenta and NeoStem.About NeoStem, Inc. NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs , which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China.For more information, please visit: www.neostem.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management&amp;#39;s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company&amp;#39;s actual results, including its success, if any, in developing adult stem cell therapies could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include without limitation whether the Company&amp;#39;s technologies will lead to successful therapeutic treatments, the Company&amp;#39;s ability to execute on its expansion plans in China and the &amp;#34;Risk Factors&amp;#34; described in the Company&amp;#39;s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company&amp;#39;s other periodic filings with the Securities and Exchange Commission. The Company&amp;#39;s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. CONTACT:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3365656>[More...]</a>]]></description>
      <pubDate>Wed, 22 Jul 2009 13:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3365656</link>
    </item>
    <item>
      <title>NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3353766</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has entered into an advisory consulting agreement with Dr. Cai Jianqian, of the Shandong Provincial Association of Chinese Medicine, to assist the company with its expansion into China and facilitate collaborations with prestigious hospitals in the Peoples Republic of China.Ms. Cai Jianqian, a graduate of Shandong University of Traditional Chinese Medicine, has held the positions of Chief of the Administration of Chinese Medicine of Shandong Province, standing Council Member of the China Association of Chinese Medicine, Chairman of the Medicated Diet Association, Member of the lecturer team on Chinese acupuncture and moxibustion, and Corporate Representative of the Shandong Provincial Association of Chinese Medicine.Ms. Cai held senior positions at China's State Drug Administration and its predecessor for many years, was responsible for creating the development strategies and long-term and middle-term planning of the industry, and is considered by many to be instrumental in the continual improvement of the standards of medicine, education and research in the Chinese medicine industry. She was appointed in 1983 to head Chinese Medical Affairs of Shandong province, and during her tenure the number of Chinese medicine hospitals in Shandong province increased from eight to 150. In addition to being responsible for having established the Shandong Academy of Chinese Medicine and the Shandong Academy of Acupuncture and Moxibustion, she has been consistently praised by the Ministry of Health and the State Administration of Traditional Chinese Medicine for having made Shandong province one of the top ranked provinces in the PRC for Chinese medicine advancement. A Council member of the American General Medical Association as well as a member of the editorial board of The Journal of American General Medicine, Ms. Cai is responsible for having established The Chinese Traditional Medicine Center in Chicago, two Chinese medicine hospitals in South Africa, twelve Chinese medicine outpatient clinics in Switzerland and the Chinese medicine rehabilitation centers in Poland and Russia. She has been extensively published in her field and is well regarded for her work in the research and development of new drugs, including the clinical study of complex diseases and acute illness, including cancer. She has been awarded an International MD and is certified by the International Open Traditional Medicine University &amp; Institute of Medical Science of the United Nations, and the International Association of Traditional Medicine in Colombo in 1999.Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, &quot;We are extremely pleased to welcome Ms. Cai to the NeoStem team and are confident that her extraordinary intellectual, administrative and political experience will guide the company as it expands abroad'. Ms. Cai stated, &quot;I'm delighted to be affiliated with NeoStem Inc. This Company's vision for collaborative medical innovation in the United States and China, especially in the field of stem cell research and applications using VSELs, opens enormous potential for both nations.&quot;About NeoStem, Inc. NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs , which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration.For more information, please visit: www.neostem.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the &quot;Risk Factors&quot; described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. CONTACT:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3353766>[More...]</a>]]></description>
      <pubDate>Thu, 16 Jul 2009 12:38:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3353766</link>
    </item>
    <item>
      <title>NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3350681</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, was featured on CBS2 News, New York City's local CBS station, on Monday evening July 13 and Tuesday morning July 14, 2009.The segment 'Go! New York' focused on the work of Dr. Christopher Centeno, a NeoStem consultant in stem cell therapies for orthopedics, and featured the success of his innovative process that rapidly grows a patient's own adult stem cells to treat a variety of musculoskeletal diseases. Interviews with Dr. Centeno at the Centeno-Schultz Clinic near Denver, Colorado, and Dr. Robin Smith, CEO of NeoStem, were included. Dr. Max Gomez, CBS2's medical expert, stated that autologous adult stem cells 'have become the cutting edge way to treat osteoarthritis of the knee, hip, and ankle and even back pain.' He noted, 'The promise appears to be so great that more than 1,000 clinical trials are testing stem cell therapies' for various conditions and 'showing promising results for heart failure, diabetes, lupus and even macular degeneration.' He added, 'That's why a company called NeoStem has begun banking people's own adult stem cells -- now, before you need them.'To see the video of the segment, please go to: http://wcbstv.com/video/?id=130168@wcbs.dayport.com NeoStem holds an exclusive royalty-bearing, perpetual and irrevocable license to use this technology of Dr. Centeno and Regenerative Sciences, Inc. in the People's Republic of China -- as announced on May 11, 2009. The first such use is anticipated to be at the Wendeng Orthopedic Hospital in Shandong, one of the leading specialist orthopedic hospitals in China. NeoStem, through its affiliate in China, is in the process of implementing a plan to offer these orthopedic treatments in China through an initial network of hospitals, of which Wendeng Hospital is the first. Dr. Centeno has been engaged to provide consulting services, including selecting a suitable PRC partner hospital and assessing and training medical staff in relation to the provision of stem cell therapies for orthopedics. Robin Smith, M.D., MBA, NeoStem&amp;#39;s Chief Executive Officer, said, &amp;#34;We are very excited to be working with Dr. Centeno to bring this therapy to China and believe that with Neostem's technology we can make the therapy less invasive and in the future there will not be the need as there is today for stem cell expansion.' As Dr. Gomez pointed out, adult stem cell therapies are being successfully applied in an increasing number of medical areas. In the past few months, NeoStem has obtained licenses to adult stem cell applications in the therapeutic areas of wound-healing and skin rejuvenation as well as orthopedics. These are the start of a pipeline of stem-cell-based regenerative medicine therapies that is a key element of NeoStem's growth strategy in both the United States and China.'As stated in the Form 8-K of July 10, 2009: 'The rationale behind NeoStem's expansion in China is to accelerate stem cell therapy, research and development and creation of intellectual property position in an environment that is more readily accepting of stem cell therapies. These initiatives will be led by U.S. researchers and physicians in collaboration with experts in the PRC for each clinical indication to be pursued. China has a large population with a rapidly growing middle and upper class who are becoming focused on regenerative medicine and can afford such services. We believe that a collaboration involving these two countries will create commercial, financial and scientific opportunities.' About NeoStem, Inc. NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs , which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration.For more information, please visit: www.neostem.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management&amp;#39;s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company&amp;#39;s actual results, including its success, if any, in developing adult stem cell therapies could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include without limitation whether the Company's technologies will lead to successful therapeutic treatments, the Company's ability to execute on its expansion plans in China and the &amp;#34;Risk Factors&amp;#34; described in the Company&amp;#39;s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company&amp;#39;s other periodic filings with the Securities and Exchange Commission. The Company&amp;#39;s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. CONTACT:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3350681>[More...]</a>]]></description>
      <pubDate>Wed, 15 Jul 2009 13:29:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3350681</link>
    </item>
    <item>
      <title>NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3333833</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has appointed Alan G. Harris, M.D., Ph.D., FACP, FRCP, as the Company's Vice President of Drug Development and Regulatory Affairs.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3333833>[More...]</a>]]></description>
      <pubDate>Mon, 06 Jul 2009 11:25:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3333833</link>
    </item>
    <item>
      <title>NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million;  Funds Will Support Expansion Activities in the United States and China as well as Further Development of NeoStem's VSEL and other Licensed Technologies</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3326602</guid>
      <description><![CDATA[NeoStem, Inc. announced today that it has raised additional gross funds of over $4 million from institutional and private investors. These funds, together with the $11 million private placement from three Asia-based investors announced April 13, 2009, bring the total investment obtained by NeoStem in the past two and half months to over $15 million. In addition, affiliates of Suzhou Erye Pharmaceuticals Company, Ltd. have increased their overall investment in the Company to over $1,000,000. As part of its China expansion activities, NeoStem is anticipating, subject to approval of its shareholders, on closing before year end on the acquisition of a 51% interest in Suzhou Erye through a merger with its current 51% owner.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3326602>[More...]</a>]]></description>
      <pubDate>Wed, 01 Jul 2009 11:25:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3326602</link>
    </item>
    <item>
      <title>/C O R R E C T I O N -- NeoStem, Inc./</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3291855</guid>
      <description><![CDATA[In the news release, NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article, issued 22-Jun-2009 by NeoStem, Inc. over PR Newswire, we are advised by the company that the fourth paragraph, third sentence, should read &quot;By 2018, he says stem cell therapy revenues could grow to $8.2 billion.&quot; rather than &quot;$8.2 million&quot; as originally issued inadvertently. The complete, corrected release follows:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3291855>[More...]</a>]]></description>
      <pubDate>Tue, 23 Jun 2009 21:10:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3291855</link>
    </item>
    <item>
      <title>NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3277947</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, was featured in Gene Marcial's prominent Business Week column, &quot;Inside Wall Street,&quot; on June 18, 2009. Also, on June 16, 2009, the expanding investment potential for adult stem cell businesses was assessed in a substantial Fortune Magazine article distributed by CNNMoney.com.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3277947>[More...]</a>]]></description>
      <pubDate>Mon, 22 Jun 2009 12:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3277947</link>
    </item>
    <item>
      <title>NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3301183</guid>
      <description><![CDATA[NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an exclusive 10-year agreement with Enhance BioMedical Holdings Limited, a Shanghai corporation, to develop a Stem Cell Collection and Treatment Network using NeoStem's proprietary adult stem cell technologies in Shanghai, Taiwan as well as the Chinese provinces of Jiangsu, Zhejiang, Fujian, Anhui and Jiangxi.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3301183>[More...]</a>]]></description>
      <pubDate>Mon, 15 Jun 2009 11:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3301183</link>
    </item>
    <item>
      <title>Form  4          NeoStem, Inc.             For: Nov 04  Filed by: VACZY CATHERINE M (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616174</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616174>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:35:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616174</link>
    </item>
    <item>
      <title>Form  4          BERNSTEIN DREW            For: Nov 04 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616172</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616172>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:32:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616172</link>
    </item>
    <item>
      <title>Form  4          Smith Robin L             For: Nov 04 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616171</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616171>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:29:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616171</link>
    </item>
    <item>
      <title>Form  4          MYERS STEVEN S            For: Nov 04 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616140</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616140>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616140</link>
    </item>
    <item>
      <title>Form  4          BERMAN RICHARD J          For: Nov 04 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616139</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616139>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:21:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616139</link>
    </item>
    <item>
      <title>Form  4          Wei Eric                  For: Nov 04 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616074</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616074>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:18:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616074</link>
    </item>
    <item>
      <title>Form  3          Wei Eric                  For: Oct 30 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616073</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616073>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 01:13:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616073</link>
    </item>
    <item>
      <title>Form  3          Zhang Jian M              For: Oct 30 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604478</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604478>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 00:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604478</link>
    </item>
    <item>
      <title>Form  4          Wei Eric                  For: Oct 30 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604464</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604464>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 00:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604464</link>
    </item>
    <item>
      <title>Form  4          Smith Robin L             For: Oct 29 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3600447</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3600447>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 02:35:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3600447</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=NBS" rel="self" type="application/rss+xml" />
  </channel>
</rss>